These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 12095379)

  • 1. Safety and tolerability of intermittent rifampin/pyrazinamide for the treatment of latent tuberculosis infection in prisoners.
    Chaisson RE; Armstrong J; Stafford J; Golub J; Bur S
    JAMA; 2002 Jul; 288(2):165-6. PubMed ID: 12095379
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of tuberculosis in Haiti.
    Long R; Scalcini M; Ollé-Goig J
    Am J Public Health; 2001 Oct; 91(10):1546-7. PubMed ID: 11574298
    [No Abstract]   [Full Text] [Related]  

  • 3. Tuberculosis: guidelines changed for latent TB treatment.
    AIDS Treat News; 2001 Sep; (371):3. PubMed ID: 11668976
    [No Abstract]   [Full Text] [Related]  

  • 4. Is the recommendation not to use rifampin plus pyrazinamide for latent tuberculosis treatment always imperative?
    Cazzadori A; Allegranzi B; Scardigli A; Favari F; Concia E
    Chest; 2004 Aug; 126(2):657-8. PubMed ID: 15302765
    [No Abstract]   [Full Text] [Related]  

  • 5. Anti-tuberculosis 4FDC tablets--mystery to chemistry.
    Dekker TG; Lötter AP
    Int J Tuberc Lung Dis; 2003 Mar; 7(3):205-6. PubMed ID: 12661831
    [No Abstract]   [Full Text] [Related]  

  • 6. [Recommendations for the therapy of tuberculosis. (Position: December, 1988)].
    Merkel S; Fischer P; Weinecke W
    Z Erkr Atmungsorgane; 1989; 173(1):87-96. PubMed ID: 2800620
    [No Abstract]   [Full Text] [Related]  

  • 7. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts.
    Schechter M; Zajdenverg R; Falco G; Barnes GL; Faulhaber JC; Coberly JS; Moore RD; Chaisson RE
    Am J Respir Crit Care Med; 2006 Apr; 173(8):922-6. PubMed ID: 16474028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group.
    Gordin F; Chaisson RE; Matts JP; Miller C; de Lourdes Garcia M; Hafner R; Valdespino JL; Coberly J; Schechter M; Klukowicz AJ; Barry MA; O'Brien RJ
    JAMA; 2000 Mar; 283(11):1445-50. PubMed ID: 10732934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rifampicin/pyrazinamide therapy should not be used for latent tuberculosis infection.
    Garca-Doval I
    J Am Acad Dermatol; 2004 May; 50(5):801; author reply 801-2. PubMed ID: 15097974
    [No Abstract]   [Full Text] [Related]  

  • 10. Acceptability of short-course rifampin and pyrazinamide treatment of latent tuberculosis infection among jail inmates.
    Bock NN; Rogers T; Tapia JR; Herron GD; DeVoe B; Geiter LJ
    Chest; 2001 Mar; 119(3):833-7. PubMed ID: 11243965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From the Centers for Disease Control and Prevention. Use of short-course tuberculosis preventive therapy regimens in HIV-seronegative persons.
    JAMA; 1998 Nov; 280(20):1736. PubMed ID: 9842936
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of latent tuberculosis infection: back to the beginning.
    Blumberg HM
    Clin Infect Dis; 2004 Dec; 39(12):1772-5. PubMed ID: 15578398
    [No Abstract]   [Full Text] [Related]  

  • 13. From the Centers for Disease Control and Prevention. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection.
    JAMA; 2002 Dec; 288(23):2967. PubMed ID: 12492097
    [No Abstract]   [Full Text] [Related]  

  • 14. Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2002 Nov; 51(44):998-9. PubMed ID: 12455909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Completing tuberculosis prophylaxis in jail: targeting treatment and a comparison of rifampin/pyrazinamide with isoniazid regimens.
    Lambert LA; Ijaz K; Navin TR
    Int J Tuberc Lung Dis; 2005 Feb; 9(2):230; author reply 230-1. PubMed ID: 15732748
    [No Abstract]   [Full Text] [Related]  

  • 16. Rifampin and pyrazinamide for treatment of latent tuberculosis infection.
    Cook PP
    Clin Infect Dis; 2006 Mar; 42(6):892; author reply 892-3. PubMed ID: 16477576
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection.
    Stout JE
    Expert Opin Drug Saf; 2004 May; 3(3):187-98. PubMed ID: 15155147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Loculated ascitis by peritoneal tuberculosis].
    de Escalante Yangüela B; Aibar Arregui M; Sáenz Abad D; Blanca Torrubia Pérez C
    An Med Interna; 2007 Apr; 24(4):205-6. PubMed ID: 17879484
    [No Abstract]   [Full Text] [Related]  

  • 19. [Centrofacial granulomatous inflammation].
    Maetzke J; Hinrichs R; Sigge A; Scharffetter-Kochanek K
    Hautarzt; 2007 Nov; 58(11):976-8. PubMed ID: 17476470
    [No Abstract]   [Full Text] [Related]  

  • 20. [Trends in tuberculosis treatment duration].
    Veziris N; Aubry A; Truffot-Pernot C
    Presse Med; 2006 Nov; 35(11 Pt 2):1758-1764. PubMed ID: 17086138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.